COMP004
36 evidence topics · 9 sources
Objective
Published study aim
“Here, we report findings from COMP 004, a 52-week observational follow-up of patients from COMP 001 and COMP 003, a small open-label study of the coadministration of 25 mg COMP360 with continuing antidepressant treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Location and study date
Study dates and identifiers
| Item | Registry record |
|---|---|
| Other study ID | “COMP004” |
| Study start (actual) | “2020-07-20” |
| Primary completion (actual) | “2022-08-11” |
| Study completion (actual) | “2022-08-11” |
| Last update posted | “2022-09-22” |
Study design
Registered design
| Item | Registry record |
|---|---|
| Study type | “Observational” |
| Observational model | “Ecologic or Community” |
| Time perspective | “Prospective” |
| Official title | “Multicentre Study To Assess Safety And Efficacy Of Psilocybin In Patients With Treatment-Resistant Depression Following Completion Of COMP 001 And COMP 003 Trials (P-TRD LTFU)” |
Follow-up structure and duration
Eligibility criteria
Registered eligibility criteria
Treatment
Interventions received in the parent studies
No study drug administered during follow-up
Study outcomes
Rationale for using time to depressive event as the primary endpoint
Primary endpoint definition
Registered outcome measures
Regulatory expectations for durability after a single psychedelic dose
Time to relapse in regulatory maintenance designs
Time to relapse as the primary endpoint in a treatment-resistant depression trial
“Cumulative distribution of time to relapse during the maintenance phase among patients who achieved stable remission (primary efficacy end point) and those who achieved stable response without remission (secondary end point) was estimated by the Kaplan-Meier method.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Relapse was defined as a MADRS total score of 22 or higher for 2 consecutive assessments separated by 5 to 15 days or hospitalization for worsening depression, suicide attempt, suicide prevention or completed suicide, or another clinically relevant event suggestive of relapse (assessed by a relapse adjudication committee).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Clinical relevance of time-to-event endpoints in psychiatric conditions
“The actual outcome in survival analysis is ‘time to event’, yet, in the mental health field, there has been little consideration of whether a temporary delay to relapse is clinically relevant in a condition that can last for decades.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“They inevitably lead to differences in time to relapse, even when there is little or no difference in the cumulative risk of relapse at final follow-up.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment: registry record
| Enrollment type | Participants |
|---|---|
| Actual | “66” |
Planned enrollment
No evidence found.
Description of analysis sets
Post hoc analysis set: participants who entered COMP004
Results
Participant disposition
Baseline characteristics
Antidepressant use at entry
Efficacy results
Median time to depressive event: published analysis
“For all COMP 001 patients (n = 233), median time to depressive event was greater for the 25 mg group (92 days) compared to the 10 mg (83 days) and 1 mg (62 days) groups, with the majority of participants having had a depressive event by Week 12 (25 mg n = 37/75, 10 mg n = 38/79, 1 mg n = 44/75).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Median time to depressive event: annual report figure for the 10 mg group
Median time to depressive event: post hoc analysis of enrolled participants
“The post hoc supplementary analysis of those who enrolled in COMP 004 from COMP 001 exhibited the difference between groups more strikingly (25 mg, 189 days; 10 mg, 43 days; 1 mg, 21 days); however, only 10 participants experienced a depressive event post-COMP 004 enrollment (25 mg n = 6, 10 mg n = 3, 1 mg n = 1) from COMP 001 and none from COMP 003.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Median time to depressive event: quarterly results statement
Health-related quality of life and patient-reported outcomes
Safety results
Serious, ongoing, and suicidality adverse events: company statement
Study limitations
Summary: observational design, selected subgroup, few events, post hoc analysis
COMP004 was an observational follow-up that enrolled 66 participants who had completed COMP001 or COMP003, 58 of them from COMP001. The prespecified primary analysis covered all COMP001 participants, and the analysis restricted to enrolled participants was post hoc and based on 10 depressive events after enrollment. At entry, more participants in the 1 mg group were taking antidepressant medication (10, compared with 9 in the 10 mg and 6 in the 25 mg group). The published and Form 10-K medians for the 10 mg group differ (83 and 86 days). The authors state that larger long-term studies are required, and FDA guidance describes blinded long-term follow-up with prespecified retreatment criteria as the most informative design.